Indevus trospium for OAB
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Indevus submits an NDA for its oral antimuscarinic agent trospium for the treatment of overactive bladder April 28. A Phase III pivotal trial, presented at the American Urological Association April 28, showed statistically significant results for the dual pre-specified endpoints of reduction in frequency of urination (toilet voids) and reduction in number of urge incontinence episodes. At week 12, trospium patients had 2.37 fewer toilet voids per day than at baseline, versus 1.29 for placebo. Incontinence episodes were reduced 59% in trospium patients versus 44% in placebo patients. Indevus is claiming a favorable side effect profile; 21.8% of trospium patients experienced dry mouth and 9.5% experienced constipation in the pivotal trial. Trospium is currently marketed in Europ
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.